A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

Study Summary

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).

Conditions

Choroidal Melanoma Indeterminate Lesions Uveal Melanoma Ocular Melanoma

Interventions / Drugs

Bel-sar Suprachoroidal Microinjector Infrared Laser Sham Infrared Laser Sham Microinjector

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment100 participants

Primary Completion—

Lead SponsorAura Biosciences

Data Retrieved2026-04-11 02:55:09.188980+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.